Beyond direct pharmacological interactions, other factors warrant consideration
Ro can take care of the prior authorization paperwork for you
Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Patients with Significant Liver Involvement: Those diagnosed with hepatic steatosis (fatty liver) or early-stage MASH, due to the potent anti-fat effects of the glucagon component on the liver
Possible mechanism GLP-1 receptor binding can trigger several pathways through activation of specific G subunits which include G and G subtypes [31]
Retatrutide is not yet FDA approved, but like many GLP-1 agonists such as Wegovy (semaglutide) and Mounjaro (tirzepatide), retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen